FDA 执法报告 D-0049-2027 将 Viatris 替米沙坦氨氯地平片超效价召回列为 III 类
FDA drug enforcement D-0049-2027: Viatris, Inc. — Superpotent Drug: potential for the Telmisartan content in these lots to exceed specifications
openFDA 执法报告 D-0049-2027 记录 Viatris 公司自愿召回替米沙坦氨氯地平片 40mg/5mg(30 片/瓶),原因是相关批次替米沙坦含量可能超出标准,属于超效价风险,被列为 III 类。
记录给出了超效价风险涉及的具体批号、有效期与分销范围,可用于核对召回边界与批次覆盖。
FDA 药品召回执法报告 — D-0049-2027
报告发布日期:2026-10-28。这是执法报告日期,不是召回启动日期。
范围:一条已分类的药品召回记录;event_id 可能归组多个产品。无召回编号的未分类记录不在本数据流范围内。本记录不是新闻稿,也不是新的执法认定。
openFDA 数据集每周更新。报告状态不是实时召回状态,不得用于跟踪召回生命周期。以下其他日期保留其各自名称所表示的含义。
完整官方产品记录(含 openFDA 统一标识符):
{
"address_1": "3711 Collins Ferry Rd",
"address_2": "",
"center_classification_date": "20261016",
"city": "Morgantown",
"classification": "Class III",
"code_info": "批号 3228113、3228114、3228115,有效期:2026年10月31日;批号 3228120、3228121,有效期:2026年11月30日。",
"country": "United States",
"distribution_pattern": "美国全国范围。",
"event_id": "100048",
"initial_firm_notification": "信函",
"more_code_info": "",
"openfda": {
"application_number": [
"ANDA202516"
],
"brand_name": [
"TELMISARTAN AND AMLODIPINE"
],
"generic_name": [
"TELMISARTAN AND AMLODIPINE"
],
"is_original_packager": [
true
],
"manufacturer_name": [
"Mylan Pharmaceuticals Inc."
],
"nui": [
"N0000000070",
"N0000175561"
],
"package_ndc": [
"0378-1075-93",
"0378-1076-93",
"0378-1077-93",
"0378-1078-93"
],
"pharm_class_epc": [
"血管紧张素2受体阻滞剂 [EPC]"
],
"pharm_class_moa": [
"血管紧张素2受体拮抗剂 [MoA]"
],
"product_ndc": [
"0378-1075",
"0378-1076",
"0378-1077",
"0378-1078"
],
"product_type": [
"人用处方药"
],
"route": [
"口服"
],
"rxcui": [
"876514",
"876519",
"876524",
"876529"
],
"spl_id": [
"c4f4323d-671d-478b-b088-008530932cee"
],
"spl_set_id": [
"ca60a4d5-ace7-4889-94ee-e2265fd63811"
],
"substance_name": [
"TELMISARTAN",
"AMLODIPINE BESYLATE"
],
"unii": [
"U5SYW473RQ",
"864V2Q084H"
],
"upc": [
"0303781075930",
"0303781076937",
"0303781078931",
"0303781077934"
]
},
"postal_code": "26505-2362",
"product_description": "替米沙坦和氨氯地平片,USP,40mg/5 mg,30片装瓶,处方药,受托生产方:Mylan Pharmaceuticals Inc., Morgantown, WV 26505 USA,印度制造,NDC 0378-1075-93。",
"product_quantity": "21,620 瓶(30片装)",
"product_type": "药品",
"reason_for_recall": "药物含量超标:这些批次中替米沙坦含量可能超出标准",
"recall_initiation_date": "20261001",
"recall_number": "D-0049-2027",
"recalling_firm": "Viatris, Inc.",
"report_date": "20261028",
"state": "WV",
"status": "进行中",
"voluntary_mandated": "自愿:企业发起"
}
来源:openFDA 已分级药品召回执法报告 · api.fda.gov